Shares of Indivior PLC (LON:INDV – Get Free Report) traded down 15.7% during trading on Friday . The company traded as low as GBX 548.71 ($6.93) and last traded at GBX 732 ($9.25). 1,888,371 shares changed hands during mid-day trading, an increase of 166% from the average session volume of 709,477 shares. The stock had previously closed at GBX 868 ($10.97).
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 1,800 ($22.74) target price on shares of Indivior in a research report on Tuesday, December 17th.
Read Our Latest Stock Report on Indivior
Indivior Trading Down 5.9 %
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
See Also
- Five stocks we like better than Indivior
- What Does a Stock Split Mean?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Dividend Payout Ratio Calculator
- DuPont’s Electronics Spinoff: The Start of Something Big
- Quiet Period Expirations Explained
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.